Australia - inglese - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - mometasone furoate, quantity: 1 mg/g - lotion - excipient ingredients: ethanol; citric acid; propylene glycol; hypromellose; purified water - for the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis.,zatamil lotion is suitable for use in scalp psoriaris and application to other areas of the body.

Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - powder for solution for instillation - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.

Australia - inglese - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - tetracycline hydrochloride - oral solution/suspension - tetracycline hydrochloride antibiotic active 200.0 g/kg - antibiotic & related - birds - ornamental | domestic birds | amazon parrot | aviary bird | budgerigar | cage birds | caged bird | canary | cockatiel | - bacterial enteritis | tetracycline sensitive bacteria | post-weaning bacterial enterit

Australia - inglese - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 200000000 cfu - injection, powder for - excipient ingredients: citric acid monohydrate; ferric ammonium citrate; strong ammonia solution; purified water; asparagine; magnesium sulfate heptahydrate; zinc formate dihydrate; lactose monohydrate; dibasic potassium phosphate; glycerol - onco tice is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. onco tice is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta or t1 - grades 1, 2, or 3) indications as at 3 october 2001: oncotice is used as a treatment ofthe urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only recommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. inidications as at 24 april 2002: oncotice is used as a treatment of primary of recurrent carcinoma in situ (cid) of the urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only reccommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.

Stati Uniti - inglese - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - protein c (unii: 3z6s89txpw) (protein c - unii:3z6s89txpw) - protein c 500 [iu] in 5 ml - ceprotin, protein c concentrate (human), is an anticoagulant indicated for neonates, pediatric and adult patients with severe congenital protein c deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. none. risk summary there are no data with ceprotin use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with ceprotin. it is also not known whether ceprotin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ceprotin has not been studied for use during labor and delivery. in the u.s. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively, regardless of drug exposure. risk summary there is no information regarding the presence of ceprotin in human milk, the effect on the breastfed infant, or the effects on milk production. ceprotin has not been studied for use in nursing mothers

Stati Uniti - inglese - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug

Stati Uniti - inglese - NLM (National Library of Medicine)

avera mckennan hospital - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug

Unione Europea - inglese - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - carcinoma, renal cell - antineoplastic agents - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced rcc. treatment of advanced renal cell carcinoma.,

Stati Uniti - inglese - NLM (National Library of Medicine)

elanco - tilmicosin phosphate (unii: smh7u1s683) (tilmicosin - unii:xl4103x2e3) - micotil is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni and for the treatment of ovine respiratory disease (ord) associated with mannheimia haemolytica . micotil is indicated for the control of respiratory disease in cattle at high risk of developing brd associated with mannheimia haemolytica . do not use in automatically powered syringes. do not administer intravenously to cattle or sheep. do not use in lambs less than 15 kg body weight. intravenous injection in cattle or sheep will be fatal. do not administer to animals other than cattle or sheep. injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats. human warnings: not for human use. injection of this drug in humans has been associated with fatalities. keep out of reach of children. do not use in automatically powered syringes. exercise extreme caution to avoid accidental self-i

Stati Uniti - inglese - NLM (National Library of Medicine)

elanco us inc. - tilmicosin phosphate (unii: smh7u1s683) (tilmicosin - unii:xl4103x2e3) - micotil is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica , pasteurella multocida and histophilus somni and for the treatment of ovine respiratory disease (ord) associated with mannheimia haemolytica . micotil is indicated for the control of respiratory disease in cattle at high risk of developing brd associated with mannheimia haemolytica . do not use in automatically powered syringes, single-use syringes, or other delivery devices not specified in the labeling. do not administer intravenously to cattle or sheep. intravenous injection in cattle or sheep will be fatal. do not use in lambs less than 15 kg body weight. do not administer to animals other than cattle or sheep. injection of tilmicosin has been shown to be fatal in swine and non-human primates. death following exposure to tilmicosin injection has been reported to fda/cvm in goats, rabbits, pheasants, pigs, dogs, deer, cats, alpacas and horses